drugset / Trial / NCT01310010
Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
Study hypothesis: Treatment with dasatinib 100 mg QD is safe and efficacious when given to patients with Ph+ ALL in the post SCT setting.
Timeline
- Start
- 2010-04
- Primary completion
- 2015-10
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasatinib anhydrous | Small molecule | 100 mg | Oral |